FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038409292> ?p ?o ?g. }

• W2038409292 endingPage "140" @default.
• W2038409292 startingPage "130" @default.
• W2038409292 abstract "Background Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. Materials and methods We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Results Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Conclusion Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF. Liver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. We injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion. Rats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen. Hepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF." @default.
• W2038409292 created "2016-06-24" @default.
• W2038409292 creator A5002301345 @default.
• W2038409292 creator A5003021411 @default.
• W2038409292 creator A5008085561 @default.
• W2038409292 creator A5013182907 @default.
• W2038409292 creator A5016822252 @default.
• W2038409292 creator A5018482813 @default.
• W2038409292 creator A5020608796 @default.
• W2038409292 creator A5029014038 @default.
• W2038409292 creator A5053765147 @default.
• W2038409292 creator A5055658784 @default.
• W2038409292 creator A5057857434 @default.
• W2038409292 creator A5070029030 @default.
• W2038409292 creator A5075867487 @default.
• W2038409292 creator A5080343609 @default.
• W2038409292 creator A5082561795 @default.
• W2038409292 creator A5086225019 @default.
• W2038409292 creator A5088420388 @default.
• W2038409292 date "2007-01-01" @default.
• W2038409292 modified "2023-10-03" @default.
• W2038409292 title "A Bioartificial Liver Device Secreting Interleukin-1 Receptor Antagonist for the Treatment of Hepatic Failure in Rats" @default.
• W2038409292 cites W1490154674 @default.
• W2038409292 cites W1515994079 @default.
• W2038409292 cites W1532411911 @default.
• W2038409292 cites W1574330564 @default.
• W2038409292 cites W1698518057 @default.
• W2038409292 cites W1967173904 @default.
• W2038409292 cites W1971200468 @default.
• W2038409292 cites W1972689256 @default.
• W2038409292 cites W1973963945 @default.
• W2038409292 cites W1981581728 @default.
• W2038409292 cites W1989459539 @default.
• W2038409292 cites W1989658278 @default.
• W2038409292 cites W1990593837 @default.
• W2038409292 cites W1992229504 @default.
• W2038409292 cites W1995997868 @default.
• W2038409292 cites W2003462212 @default.
• W2038409292 cites W2009008191 @default.
• W2038409292 cites W2010255267 @default.
• W2038409292 cites W2028325678 @default.
• W2038409292 cites W2033455236 @default.
• W2038409292 cites W2035274613 @default.
• W2038409292 cites W2037118265 @default.
• W2038409292 cites W2037230449 @default.
• W2038409292 cites W2046163528 @default.
• W2038409292 cites W2048656662 @default.
• W2038409292 cites W2049311225 @default.
• W2038409292 cites W2053380909 @default.
• W2038409292 cites W2057210516 @default.
• W2038409292 cites W2062652813 @default.
• W2038409292 cites W2067420120 @default.
• W2038409292 cites W2071268435 @default.
• W2038409292 cites W2072993053 @default.
• W2038409292 cites W2074393911 @default.
• W2038409292 cites W2111389460 @default.
• W2038409292 cites W2119636014 @default.
• W2038409292 cites W2121640904 @default.
• W2038409292 cites W2165137061 @default.
• W2038409292 cites W2165389354 @default.
• W2038409292 cites W2415178610 @default.
• W2038409292 cites W61425884 @default.
• W2038409292 cites W95884546 @default.
• W2038409292 doi "https://doi.org/10.1016/j.jss.2006.08.009" @default.
• W2038409292 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3201777" @default.
• W2038409292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17081566" @default.
• W2038409292 hasPublicationYear "2007" @default.
• W2038409292 type Work @default.
• W2038409292 sameAs 2038409292 @default.
• W2038409292 citedByCount "21" @default.
• W2038409292 countsByYear W20384092922012 @default.
• W2038409292 countsByYear W20384092922013 @default.
• W2038409292 countsByYear W20384092922014 @default.
• W2038409292 countsByYear W20384092922015 @default.
• W2038409292 countsByYear W20384092922016 @default.
• W2038409292 countsByYear W20384092922017 @default.
• W2038409292 countsByYear W20384092922019 @default.
• W2038409292 countsByYear W20384092922020 @default.
• W2038409292 crossrefType "journal-article" @default.
• W2038409292 hasAuthorship W2038409292A5002301345 @default.
• W2038409292 hasAuthorship W2038409292A5003021411 @default.
• W2038409292 hasAuthorship W2038409292A5008085561 @default.
• W2038409292 hasAuthorship W2038409292A5013182907 @default.
• W2038409292 hasAuthorship W2038409292A5016822252 @default.
• W2038409292 hasAuthorship W2038409292A5018482813 @default.
• W2038409292 hasAuthorship W2038409292A5020608796 @default.
• W2038409292 hasAuthorship W2038409292A5029014038 @default.
• W2038409292 hasAuthorship W2038409292A5053765147 @default.
• W2038409292 hasAuthorship W2038409292A5055658784 @default.
• W2038409292 hasAuthorship W2038409292A5057857434 @default.
• W2038409292 hasAuthorship W2038409292A5070029030 @default.
• W2038409292 hasAuthorship W2038409292A5075867487 @default.
• W2038409292 hasAuthorship W2038409292A5080343609 @default.
• W2038409292 hasAuthorship W2038409292A5082561795 @default.
• W2038409292 hasAuthorship W2038409292A5086225019 @default.
• W2038409292 hasAuthorship W2038409292A5088420388 @default.
• W2038409292 hasBestOaLocation W20384092922 @default.
• W2038409292 hasConcept C126322002 @default.

• next